PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsGenetic Testing and Molecular GeneticsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient ResultsNew Clinic or Provider Information Changes
Pathology and Laboratory Medicine
Product Catalogue


Transfusion Medicine

Factor Complex, Human
Alternate Product Name:
Human Von Willebrand Factor (VWF) and Human Coagulation Factor VIII (FVIII)
Octapharma Canada Inc.


​Direct IV
​Intermittent IV Infusion
​Continuous Infusion
​Acceptable Routes

  • Wilate is a plasma-derived, stable, highly purified concentrate of freeze-dried active human von willebrand factor (VWF) and caogulation factor VIII (8)
  • It is prepared from cryopreceipitate
  • Wilate is supplied as a white sterile lyphilized powder and solvent for solution for intravenous injection using the provided injection set
  • VWF: FVIII ratio 1:1​
  • Vial sizes/dosages:
    • 500 units VWF and 500 units FVIII reconstituted with 5 ml of diluent
    • 1000 units VWF and 100 units FVIII reconstituted with 10 mL of diluent​
  • Supplied by Canadian Blood Services (CBS)
  • Contact your local laboratory/transfusion laboratory service regarding in house stock availability at your site
  • Hemophilia A: Treatmnet and prophylaxis of bleeding in patients with hemophilia A (congenital or acquired FVIII (8) deficiency) and for the prevention and treatment of bleeding in minor surgical procedures
  • Von Willebrand Disease (VWD): Treatment and prevention of spontaneous and trauma-induced bleeds in all types of VWD in asdults and pediatric patients where use of DDAVP(1-deamino-8-D-arginine vaspressin/desmopressin) treatment is ineffective or contraindicated. Prevention and treatment of bleeding during and after surgical procedures
  • Treatment should be initiated and supervised by a healthcare practitioner experienced in the use of coagulation agents and in the management of bleeding disorders​
  • Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container
  • For a complete listing, see the contraindications section of the product monograph
  • Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, discontinue treatment and follow adverse event protocol. See ​Nursing Polcy and Procedure Blood Components and Plasma Protein Product - Administration of #1141
  • Development of factor VIII (8) neutralizing antibodies (inhibitors) may occur. If expected plasma factor VIII (8) activity levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay that measures factor VIII inhibitor concentration should be performed
  • This product is prepared from large pools of human plasma, which may contain the causative agents of hepatitis or other viral diseases. The physician should discuss the risks and benefits of this product with the patient before prescribing or administering to the patient. A physician experienced in the care of bleeding disorder patients should be consulted in the case of suspected factor VIII (8) inhibitor
  • Dosage should be determined by a physician experienced in the care of bleeding disorder patients
  • For further infromation about dosage please review the product monograph
  • Individual dosing may vary based on body weight, laboratory values, clinical response and pharmacokinetics in patients
  • Consult with Hematologist or the Saskatchewan Bleeding Disorder Program for safe dosing recommendations by paging through Switchboard at (306)655-1000​
Pre-Administration Testing Requirements
  • Specify type of coagulation concentrate and dosage required
  • Off label requests for anyone other than bleeding disorder patients must be approved by the Transfusion Medicine Physician. Contact them through switchboard at (306)655-1000
  • To request product from the transfusion medicine laboratory, use the "Plasma Protein Product Request Form" #103221​
​Forms Required
  • ​Informed Consent for Blood Components and/or Plasma Protein Products #101479
  • Plasma Protein Product Request Form #103221
  • Transfusion/Infusion Administration and Assessment Record #101059
  • Saskatchewan Transfusion Adverse Event Report Form #103695 (only needed if adverse even occurs)
  • Notification of Administration of Blood and/or Blood Products Form #103854
  • Forms can be located in the Lab Services Manual or Forms on Demand
Supplies Required
  • Each carton of Wilate includes the following:
    • A single-use vial of Wilate lyophilized powder
    • A vial with solvent (5 mL or 10 mL based concentration of the vial)​
    • A Mix2Vial transfer set with integrated filter
  • Additional supplies needed:
    • One butterfly infusion set (can use if patient does not have an IV in place)
    • One luer lock syringe (appropriate size based on volume) for administration
    • Sterile alcohol swabs (for cleaning the tops of the vials)
  • Blood consent: is required due to it being prepared from cryoprecipitate
  • Pre-Infusion: Ensure recent patient weight is on file and pertinent laboratory results are available
  • Perform all other appropriate pre-administration checks as per protocol, detailed in the Nursing Policy and Procedure Blood Compoinents and Plasma Protein Product - Administration of #1141​
  • Administration:
    Administer the entire dose at a rate of 2-3 mL per minute
  • For additional preparation/reconsitution and administration steps see administration section of the Product Monograph
  • Access: can be given via CVC, PICC, Port-a-Cath, or peripheral IV
  • Compatible Solutions: Can flush line with 0.9% normal saline pre and post administration of Wilate. No toher drugs/solutions (including normal saline) can be co-administered in the same line while Wilate is being infused
  • Preparation and Reconstitution
    • Reconstitute only immediately before administration
    • Administer within 3 hours of reconstitution
    • DO NOT refrigerate after reconstitution
    • DO NOT further dilute in any IV solutions
    • DO NOT mix with other drugs or IV solutions
Use aseptic technique (clean and germ free) when preparing and reconstituting Wilate
Allow the vials of Wilate and diluent to reach room temperature before use. This can be done by warming of both unopened vials in your hands to a comfortable temperature or by leaving the unopened vials at room temperature for about half an hour prior to administration. Warming of the vials will ease with dissolving the powder and lessen patient discommfort in the vein when administering
​Remove the flip caps from both the Wilate vial and the solvent vial and clean the rubber stoppers with an alcohol swab
​Peel away the lid of the outer package of the Mix2Vial transfer set. Place the solvent vial on an even surface and hold the vial firmly. Take the Mix2Vial together with its outer package and invert it over the solvent vial. Push the blue plastic cannula of the Mix2Vial firmly through the rubber stopper of the solvent vial (fig. 1)
Wilate Fig 1.gif
​While holding onto the solvent vial, carefully remove the outer package from the Mix2Vial, being careful to leave the Mix2Vial attached firmly to the solvent vial (fig. 2)
Wilate Fig 2.gif
​With the Wilate vial held firmly on an even surface, quickly invert the solvent vial (with the Mix2Vial attached) and push the transparent plastic cannula end of the Mix2Vial firmly through the stopper of the Wilate vial (fig. 3) The solvent will be drawn intol the Wilate vial by vacuum
Wilate Fig 3.gif
​With both vials still attached, slowly (careful not to introduce bubbles) swirl the Wilate vial to ensure the product is fully dissolved, giving a clear or slightly opalescent, colorless or slightly yellow solution. Once the contents of the Wilate vial are dissolved, firmly hold both the transparent and the blue parts of the Mix2Vial. Unscrew the Mix2Vial into two separate pieces with the vials still attached (fig. 4) and discard the empty solvent vial and the blue part of the Mix2Vial
Wilate Fig 4.gif
​Attach a plastic sterile disposable syringe to the transparent part of the Mix2Vial. Invert the system and draw the reconstituted Wilate into the syringe. Once the Wilate solution has been transferred into the syringe, firmly hold the barrel of the syringe (keeping it facing down) and detach the Mix2Vial from the syringe. Discard the Mix2Vial (transparent plastic part) and the empty Wilate vial

​Clean the intended injection site with an alcohol swab
  • Lab testing post administration: As directed by most responsible healthcare practitioner
Nursing Implications
  • Patient monitoring: Follow the Nursing Poilicy and Procedure Blood Components and Plasma Protein Product - Administration of #1141
  • Documentation: Administration and vital signs shall be recorded on the Transfusion/Infusion Administration and Assessment Record #101059​
Adverse Events
  • Allergic reactions are possible with administration of blood components and plasma protein products ranging from mild to life threatening
  • Refer to Nursing Policy and Procedure Blood Components and Plasma Protein Product - Administration of #1141 for managing of allergic transfusion reaction and call MRHP
  • Document adverse event on Saskwatchewan Transfusion Adverse Even Report Form #103695 whether or not the transfusion was discontinued​
  • Can contact the Saskatchewan Bleeding Disorders Program for education and administration assistance at (306)381-4185, Monday to Friday, 0800-1630

If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-1010 v1

Last Modified: Thursday, April 16, 2020 |
Questions or feedback about this page?